
    
      This Phase II randomized, placebo-controlled, double-blind study will assess whether topical
      GLS-1200 applied via nasal spray atomizer is well-tolerated and can reduce the incidence of
      confirmed SARS-CoV-2 infection. Subjects will be randomized to either the GLS-1200 or placebo
      group in a 2:1 ratio with a target enrollment of 225 subjects. Subjects will self-administer
      study drug three times daily for 4 weeks.
    
  